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Abstract 
Adult T-cell leukemia-lymphoma (ATLL) is an HTLV-1-associated 
lymphoproliferative malignancy that is frequently fatal. We compared gene expression 
profiles (GEPs) of leukemic specimens from 9 patients with ATLL at the time of 
diagnosis and immediately after combination therapy with zidovudine (AZT) and 
interferon alpha (IFNα). GEPs were also related to genetic aberrations determined by 
comparative genomic hybridization. We identified several genes anomalously over-
expressed in the ATLL leukemic cells at the mRNA level, including LYN, CSPG2 and 
LMO2, and confirmed LMO2 expression in ATLL cells at the protein level. In vivo AZT-
IFNα therapy evoked a marked induction of interferon-induced genes accompanied by 
repression of cell-cycles regulated genes including those encoding ribosomal proteins. 
Remarkably, patients not responding to AZT-IFNα differed most from responding 
patients in lower expression of these same IFN-responsive genes, as well as components 
of the antigen processing and presentation apparatus.  Demonstration of specific gene 
expression signatures associated with response to AZT-IFNα therapy may provide novel 
insights into the mechanisms of action in ATLL. 
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Introduction 
Adult T-cell leukemia-lymphoma (ATLL) is a highly aggressive T-cell 
malignancy etiologically linked to the retrovirus Human T-cell Leukemia Virus type I 
(HTLV-1)1. HTLV-1 is transmitted mainly through breastfeeding, sexually and blood 
transfusions and is endemic in areas of southern Japan, the Caribbean basin, intertropical 
Africa, South America, the Middle East and Papua New Guinea. An estimated 15-20 
million people are infected with HTLV-1 worldwide, the majority of whom are 
asymptomatic carriers2. Nevertheless, 2-6% of infected individuals will develop ATLL 
over a 40-60 year period. This very long latency and the low incidence of ATLL 
development in carriers suggest that the oncogenic potential of the HTLV-1 virus is quite 
weak and that secondary genetic events must somatically arise within infected cells 
during transformation. Current data supports the view that the viral Tax protein is 
instrumental for oncogenesis as has been demonstrated in in vitro transformation assays 
and animal models3. The Tax protein affects multiple intracellular processes and 
signaling pathways, including cell cycle progression, cell survival, mitosis and genomic 
stability4-6. Surprisingly, however, tax transcripts are detected in only 40% of all primary 
ATLL tumors7,8, further pointing to the complexity of the HTLV-1-induced 
transformation and oncogenesis process, the mechanisms of which remain to be 
elucidated. 
Clinically, ATLL is subdivided into four subtypes: acute, lymphoma-type, chronic 
and smoldering9. The first two types show aggressive clinical courses with median 
survival ranging from 7-13 months9. Although diverse therapeutic approaches have been 
used, standard or dose-intense chemotherapy regimens result in low response rates and 
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response durations are typically short. Accordingly, novel therapeutic approaches based 
on a better understanding of this disease are needed.  In this context, several novel 
approaches include unlabelled and radiolabelled anti-CD25 monoclonal antibodies10, as 
well as strategies targeting the NFkB pathway11,12 and chemokine CCR4 receptor13. In 
addition, promising results have been observed in ATLL patients treated with a 
combination of zidovudine (AZT) and interferon alpha (IFNα) 14-17.  
To further investigate the deregulated pathways that may contribute to HTLV-1-
mediated oncogenesis in ATLL, including the mechanisms that may underlie therapeutic 
responsiveness, we performed microarray gene expression analyses on ATLL specimens 
obtained at the time of diagnosis and immediately following combination therapy with 
AZT and IFNα. Further, correlation of patient cytogenetic profiles with patient gene 
expression data was performed to determine specific genetic aberrations resulting in over 
or under expression of genes that may contribute to disease pathogenesis. Our studies 
define a gene expression signature characteristic of ATLL cells, and reveal novel genes 
associated with response to AZT-IFNα therapy. These data may serve to predict 
individual responses to these compounds, thus helping to tailor treatment in patients with 
ATLL.  
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Materials and Methods 
 
Patients and Treatment Regimen 
The diagnosis of acute ATLL was  based on characteristic clinical features, 
immunophenotype, and serological evidence of HTLV-1 antibody by ELISA, which was 
confirmed by Western blot and/or monoclonal proviral integration. The study group 
consisted of nine patients with leukemic presentation of HTLV-1 ATLL, all of whom 
provided informed consent, in accordance with the Declaration of Helsinki. Institutional 
review board (IRB) approval for these studies was granted by the IRB of the University 
of Miami. 
All patients were treated with a uniform induction regimen combining high dose 
parenteral AZT (1.5 grams administered twice daily) and IFNα (5-10 million units 
administered twice daily) as induction therapy, a standard approach at our institution for 
patients with ATLL at the time of this study. Patients who responded to this induction 
regimen continued to receive outpatient maintenance therapy in the form of oral AZT 
(600 mg twice daily) and subcutaneous IFNα (5 million U once or twice daily). For 
patients with prolonged clinical response, maintenance therapy was gradually tapered to 
twice-daily oral doses of 300 mg AZT and 3 times weekly subcutaneous injections of 3 
million U of IFNα.  ‘Clinical response’ was defined as the disappearance of circulating 
abnormal lymphocytes, hypercalcemia, organomegaly, and measurable disease lasting for 
at least one month.  
 
Isolation of PBMCs from ATLL patients and cell lines  
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Peripheral blood mononuclear cells (PBMCs) from nine patients with ATLL at 
the time of initial presentation and 24 hours post initial therapeutic dose (6 patients) were 
obtained and immediately processed for PBMC separation using density gradient 
centrifugation (Lymphoprep; MediaTech, Herndon, VA). In all the patients ATLL 
leukemic cells represented the majority of PBMCs at both time points.  After separation, 
PBMCs were washed in sterile phosphate buffered saline, snap frozen as pellets and 
stored at -80 C for later use.  The HTLV1 positive cell line MT2, the CD4-positive 
lymphoblastic leukemia cell line Jurkat (HTLV1-negative), and the diffuse large B-cell 
lymphoma cell line SU-DHL6 (HTLV1-negative) were grown in RPMI 1640 medium 
(Fisher Scientific, Santa Clara, CA) supplemented with 10% fetal calf serum, 2 mM 
glutamine (GIBCO BRL, Grand Island, NY), and penicillin/streptomycin (GIBCO BRL). 
MT2 cells were treated with AZT (10 micrograms/ml) and IFNα (1,000 units/ml; 
Schering-Plough Corporation, Kenilworth, N.J.) in vitro. For this project, the cell lines 
were given code names (LLAT7A and B for untreated and treated MT2 cells and LLAT8 
for Jurkat) and investigators that performed initial gene expression analysis were blinded 
to the nature of the cell line specimens. For each of 6 patients (LLAT1 through LLAT6), 
and 1 cell line (LLAT7), corresponding sample pairs representing baseline pre-therapy 
specimens and specimens representing the 24-hour time point following therapy with 
AZT-IFNα were coded as “A” and “B”, respectively. 
Immunoblot analyses  
Whole-cell extracts for immunoblot analysis were prepared by lysing 5-10 x 106 
cells with RIPA buffer (1 x phosphate-buffered saline [PBS], 1% Nonidet P-40, 0.5% 
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sodium deoxycholate, 0.1% SDS, 10 mM phenylmethylsulfonyl fluoride, 1 µg/mL 
aprotinin, and 100 mM sodium orthovanadate) on ice for 30 minutes. After centrifugation 
at 3000g, the supernatant was assayed for protein concentration by bicinchoninic acid 
(BCA) assay (Pierce Biotechnology, Rockford, IL). For immunoblotting, 40 µg of whole-
cell lysate was separated on 10% SDS–polyacrylamide gel electrophoresis, transferred to 
polyvinylidene difluoride membranes (BioRad Laboratories, Hercules, CA), and probed 
with anti-LMO2 antibody previously generated by us18 at 1:1000 dilution and anti–ß-actin 
antibodies at 1:10 000 dilution (Sigma, St Louis, MO) overnight at 4°C. These antibodies 
were detected using anti–mouse horseradish peroxidase (HRP)–conjugated antibodies at 
1:10 000 dilution (Jackson Immuno Research Laboratories, West Grove, PA) and 
visualized by the Super Signal West Femto Luminol/Enhancer Solution and Super Signal 
West Pico Luminol/Enhancer Solution  (Pierce Biotechnology), respectively.  
Gene expression profiling  
Total cellular RNA was isolated from the tumor specimens and cell lines by using 
the RNeasy kit (Qiagen) according to the manufacturers’ instructions.  Starting from 3-4 
micrograms of total RNA, one round of linear amplification was used to prepare 
amplified RNA (MessageAmp, Ambion).  In each experiment, fluorescent cDNA probes 
were prepared from an experimental amplified RNA (aRNA) sample (Cy5-labeled) and a 
reference aRNA sample (Cy3-labeled); the latter used Universal Human Reference RNA 
(Stratagene), isolated from a pool of 11 cell lines (MCF7, Hs578T, NTERA2, Colo205, 
OVCAR-3, UACC-62, MOLT-4, RPMI-8226, NB4+ATRA, SW872, and HepG2). The 
use of a common reference allows the determination of the relative expression of each 
gene across all of the samples19.  Fluorescent cDNA probes were then hybridized to 
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microarrays fabricated at the Stanford Functional Genomics Facility (generation SHDW; 
NCBI GEO GPL3522). The microarrays used included a total of 41,805 features 
representing 41,409 unique cDNA clones; these clones correspond to approximately 
27,319 unique UniGene clusters including at least 14,744 unique named known genes 
(NCBI UniGene build number 173). Microarrays were hybridized then washed using 
previously described conditions19, and then scanned on a GenePix 4000B scanner (Axon 
Instruments). The data from the microarray experiments is available at the GEO database 
(http://www.ncbi.nlm.nih.gov/geo/) with accession number GSE19160. 
 
Statistical Methods  
Microarray data were deposited into the Stanford Microarray Database, where 
raw data were normalized using a regression based correlation scheme.  Data selection 
included filtering for well-measured features using the ratio of feature intensity over local 
background exceeding 2.5 fold for at least 70% of the 18 arrays (n= 9606 features).  
Variant features (n=965) were selected by filtering for probes exhibiting a difference 4-
fold or more from the median expression level in at least 3 of 18 (15%) microarrays.  
Unsupervised analysis was then performed by agglomerative hierarchical clustering using 
average-linkage that was applied sequentially to both genes and experiments (both 
median-centered) using the CLUSTER 3.0 program (http://bonsai.ims.u-
tokyo.ac.jp/~mdehoon/software/cluster/software.htm), and the results were analyzed with 
TREEVIEW (http://rana.lbl.gov/EisenSoftware.htm).  
For supervised analyses of gene expression changes upon treatment with AZT-
IFNα, Significance Analysis of Microarrays (SAM) 20 was applied to all paired samples 
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with available baseline pre- (“A”) and post- AZT-IFNα therapy (“B”) specimens, starting 
with the data matrix of 9606 features described above.  After imputing missing values 
through K-nearest neighbors (K=10), the paired metric was applied and a threshold FDR 
of 15% was set using the MeV 4.4.1 software package 21 to identify 150 significant 
features.  For display purposes, paired samples were displayed as the difference in log-
ratios between the “B” and “A” samples, and then hierarchically clustered.  To assess 
biological enrichment in response to AZT-IFNα, we applied Gene Set Enrichment 
Analysis (GSEA v2.0.4, using default parameters) 22 to the pre-ranked list of features as 
defined above using the paired SAM statistic; we supplemented gene sets within the 
Molecular Signatures Database (mSIGDB, Broad Institute) 22 with those from the 
immunological Signatures Database (SIGDB, National Cancer Institute, NIH) 23 as 
previously described 24.  For supervised analyses of gene expression differences among 
responding and non-responding patients to AZT-IFNα, SAM was applied to all pre-
therapy (A) patient specimens, starting with the data matrix of 9606 features described 
above.  After imputing missing values through K-nearest neighbors (K=10), the 2-class 
metric was applied to distinguish responding patients (LLAT1, 2, 3, and 4) versus non-
responding patients (LLAT5, 6, 9, 10, and 11). To assess biological processes 
distinguishing responders from non-responders, we again applied GSEA to the pre-
ranked list of features as defined above using the SAM statistic. 
 
Comparative genomic hybridization (Array CGH)  
High molecular-weight DNA was extracted from 5 million cells with a 
commercially available kit as described by the manufacturer (QIAamp Tissue Kit; 
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Qiagen, Valencia, CA). To measure DNA copy number changes throughout each tumor 
genome, standard comparative genomic hybridization was applied to chromosomes (s-
CGH) to eight samples, using a reported method25. Additionally, two cases were selected 
and studied in higher detail through array-based CGH using a validated microarray 
containing 2.460 BAC and P1 clones spotted in triplicate (UCSF Hum Array 2.0) and 
representing an average genomic resolution of 1.4 Mb. Relevant experimental methods 
and analytical procedures for array CGH have previously been described elsewhere in 
detail26.  
 
Results 
Clinical profile of studied ATLL patients 
Nine HTLV-1 associated ATLL patients with acute leukemia subtype were 
analyzed. The white blood cell counts at presentation ranged from 10-182 x109/L with 
absolute leukemic lymphocyte counts ranging from 6-153 x109/L. Flow cytometric 
analyses demonstrated that leukemic cells from all the patients expressed CD4 and CD25 
that stained brightly on the cells. HTLV-1 proviral genome in leukemia cells was 
detected by Southern blot hybridization or PCR analysis. Among the 9 patients with 
ATLL, 6 also presented with lymphadenopathy. Splenomegaly and hypercalcemia were 
separately detected in 5 patients each.  
Upon confirmation of the diagnosis, all patients received AZT- IFNα combination 
therapy. Durable response was observed in 4 patients. (LLAT1, LLAT2, LLAT3 and 
LLAT4), though the durability of these response varied (overall survival range  of 0.67-
8.20 years; patient LLAT1 survived for 6.3 years and only patient LLAT2 remains alive 
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at the last follow-up, 8.20 years since diagnosis). In contrast, all non-responding patients 
succumbed to complications of their disease and died within 0.25-1.00 years following 
the diagnosis of ATLL. 
 
Gene expression profiles of HTLV-1+ ATLL 
 We next explored genome-wide expression profiles obtained from peripheral 
blood leukemic lymphocytes from diagnostic blood specimens of these nine patients. In 
six patients (LLAT1, LLAT2, LLAT3, LLAT4, LLAT5 and LLAT6), we also analyzed 
GEPs of peripheral blood leukemic lymphocytes obtained 24 hours after initiation of 
AZT-IFNα combination therapy. As controls, we also included GEPs of the HTLV-1+ 
ATLL cell line MT2 (LLAT7) before and after in vitro AZT-IFNα treatment, as well the 
HTLV-1 negative Jurkat line (LLAT8). Unsupervised hierarchical clustering of 
specimens based on these genes revealed that distinct GEPs distinguished both 
transformed leukemic cell lines (i.e., MT2/LLAT7 and Jurkat/LLAT8) from the primary 
clinical specimens from patients with HTLV-1+ ATLL, as it resulted in their separate 
clustering (Figure 1). Among GEP features associated with this distinction, we observed 
differential expression of genes associated with proliferation, whose expression was high 
in the MT2 cell line, as reflected in a signature comprising many cell cycle associated 
genes including PCNA, CCNB1,  CCNA2, CDC2, CDK4, CDC25A, and CDCA1. 
Notably, many of these genes were previously reported as being over-expressed in 
HTLV-1 infected cell lines1,27-30.  
In contrast, primary leukemic cells from patients’ peripheral blood demonstrated 
significantly higher expression of several surface cell markers, such as CD52, CD37, 
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CD28, and CD97. In addition, expression of histocompatibility genes such as HLA-E and 
HA-1 was higher in primary leukemic samples compared to the cell lines. These 
observations suggest that despite the fact that MT2 cell line is commonly used for 
research of HTLV-1 related ATLL, it may not be representative of primary leukemic 
cells.  Therefore, we excluded MT2 cell line from subsequent analyses. Overall,                                       
distinct clones representing the same gene typically clustered in adjacent rows in this 
gene-map, indicating that each gene has a distinct pattern of expression and that 
expression measurements are sufficiently precise to distinguish them. 
 Expression of several genes that have been previously reported to be induced in 
Tax-expressing cells was observed to be increased in ATLL cell compared to the Jurkat 
cells (e.g. IL2Rα, IL2Rβ and major histocompatibility complex class II genes)31. Overall, 
when focusing on genes exhibiting significant differences between primary diagnostic 
ATLL leukemia specimens in comparison with the Jurkat cell line (i.e., at least 4 fold in 
at least 8 of 9 patients with ATLL), 122 arrayed features were reproducibly over-
expressed and 50 features had lower expression in ATLL (Supplemental Table 1).  
Multiple genes previously reported as expressed at higher levels in ATLL cells 
compared to normal CD4 lymphocytes were also found to be expressed at markedly 
higher levels in our ATLL leukemic cells compared to Jurkat cell line (e.g. LYN, LYZ, 
S100A8, S100A9)30. Our analysis separately identified several genes highly expressed in 
the ATLL cells that may have an important role in pathogenesis of this disease. Among 
these genes, for example, we identified LMO2, which encodes a transcription factor 
regulating key events in erythropoiesis, angiogenesis, and embryogenesis32.  
Homozygous mice deficient in LMO2 die as a result of defective yolk sac erythropoiesis, 
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whereas heterozygous mice show that LMO2 plays a role in the development of all bone 
marrow–derived hematopoietic lineages33. While LMO2 is not expressed in normal T 
cells, this gene is of relevance in T-cell lymphoid and myeloid leukemias resulting from 
the deregulated expression of LMO2 as caused by chromosomal translocations and 
insertional mutations34. Notably, the over-expression of LMO2 mRNA in leukemic cells 
of patients with ATLL cell observed herein was also reported in a previous study30. 
 To further examine whether LMO2 protein is also expressed in ATLL leukemic 
cases, we performed Western blot analysis (Figure 2). All analyzed primary ATLL cases 
demonstrated LMO2 protein expression, with significant correlation between LMO2 
mRNA and protein expression (data not shown). Consistent with prior reports35, no 
expression was observed in the Jurkat cell line. Furthermore, LMO2 was neither 
expressed at the mRNA nor at the protein level in the MT2 cell line, further confirming 
differences in gene expression between primary ATLL specimens and this HTLV-1 
infected cell line. Our finding of LMO2 expression in the ATLL leukemic T cells 
suggests that it may have a role in HTLV-1 induced leukemogenesis, similar to its known 
role in T-cell acute lymphoblastic leukemia. 
Chondroitin sulfate proteoglycan core protein 2 (CSPG2) expression was also 
elevated in ATLL leukemic cells as compared to the Jurkat cells. Of note, CSPG2 
expression was also previously reported to be higher in ATLL cells compared to CD4 
lymphocytes30. CSPG2 may play an important role in cancer cell migration and 
proliferation, and was reported to be elevated in adenomas and carcinomas36,37. 
Interestingly, CSPG2 is positively regulated by β-catenin, which is increased in ATLL 
cells38,39.  
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Among our series of patients with ATLL, in all cases leukemic cells demonstrated 
at least 2-fold over-expression of CX3CR1 compared to Jurkat cells, similarly to a prior 
report30. CX3CR1 is a typical seven transmembrane G-protein-coupled receptor involved 
in adhesion and chemotaxis40, which binds its ligand, CX3CL1, a membrane bound 
adhesion molecule. CX3CL1 expression on endothelial cells promotes the metastasis of 
CX3CR1 expressing tumor cells, as reported for both prostate and breast cancer and is 
associated with an increased risk of metastasis to the brain41,42. Similar to the expression 
of CCR7 in T-cell acute lymphoblastic leukemias43, CX3CR1 over-expression on the 
ATLL cells may be associated with parenchymal organ infiltration. 
 
Gene expression signatures of response to AZT-IFNα 
In unsupervised analyses, comparison of the pre- and post AZT-IFNα therapy 
specimens demonstrated that paired specimens derived from individual patients almost 
invariably clustered together, indicating that intrinsic differences in gene expression 
among individual patients were more pervasive than the early expression responses 
induced by AZT-IFNα (Figure 1).  Nonetheless, despite baseline variation in expression 
of responsive genes, comparison of paired specimens from individual patients before and 
after therapy revealed a concerted signature of transcriptional responses to AZT-IFNα 
treatment (Figure 3A).  Using Gene Set Enrichment Analysis (GSEA), these responses 
were strikingly enriched for induction of genes known to be responsive to IFN in diverse 
cell types (Figure 3B) and for repression of those associated with ribosomal biogenesis, 
cell-cycle regulation, and proliferation (Figure 3C). . 
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We observed that the inter-individual heterogeneity among these ATLL patients 
captured gene expression differences relating to their clinical responses to this regimen.  
Unsupervised analyses revealed that three of the four cases demonstrating a clinical 
response to AZT-IFNα treatment clustered together on the same dendrogram branch, 
while the two paired specimens derived from patients that did not exhibit response 
clustered separately (Figure 1).  We applied supervised analyses to explicitly assess 
differences between signatures of responders to AZT-IFNα and non-responders using 
GSEA.  Notably, despite exhibiting similar response profiles to AZT-IFNα in the 
magnitude of induction and repression (Figure 3A), patients responding to AZT-IFNα 
differed most from non-responding patients in their baseline relative over expression of 
IFN-responsive genes, as well as components of the antigen processing and presentation 
apparatus (Table 1).  Conversely, non-responding patients showed relative over-
expression of E2F3 and many of its proliferation-associated oncogenic targets(Table 1).   
 
Correlation of genomic and gene expression data 
HTLV-1 harboring ATLL tumors frequently carry chromosomal aberrations that 
may or may not be evident on routine metaphase karyotypes. Consequently, the tumor 
genomic profiles were examined and DNA copy number changes were correlated with 
gene expression profiles. Genomic analysis was performed on 8 tumor samples prior to 
therapy using comparative genomic hybridization (genomic DNA was not available for 
one patient). Overall, all but one case harbored clonal genomic imbalances. The pattern 
of genomic aberrations in HTLV-1+ ATLL specimens consisted of 49 genomic 
 16
imbalances (mean per tumor: 6.125 range: 0-16) and included 15 genomic gains (mean 
per tumor: 1.875 range: 0-6) and 34 losses (mean per tumor: 4.25 range: 0-15).  
The most common chromosomal changes included gains of regions 1q, 3p, and 3q 
and losses of chromosomal regions 4p, 6q, 9p, 10p, 10q, 16p, 16q, and 17p (Figure 4A). 
Using array-based CGH, these genomic aberrations were then characterized at higher 
genomic resolution for two cases (Figure 4B). Despite the anomalous expression of 
LMO2 in our ATLL patients, no aberrations were detected at the corresponding 
cytogenetic interval locus 11p13, suggesting that LMO2 expression in ATLL cells is not 
due to a genomic amplification.   
We next searched for genes within amplified or deleted genomic loci that were 
correspondingly over or under expressed at least 1.5 fold compared to the average 
expression of the series. This analysis revealed 110 genes located in areas of genomic 
imbalances (Table 2), though only three of the genes (MET2A, IFIT1, and IL2RA) 
exhibited relative down-regulation in at least two cases with similar chromosomal losses. 
Of note, expression of MET2A and IFIT1 was also relatively down-regulated in some 
cases without chromosomal aberrations suggesting alternative mechanisms.  Separately, 
despite our observation of over-expression of E2F3 and its targets among non-responding 
patients, we did not observe recurrent amplifications involving the corresponding 
genomic locus for E2F3 (i.e., 6p22.3) by comparative genomic hybridization of patients 
with ATLL (Figure 4A).  Prior study demonstrated amplification of E2F3 and over-
expression of its target genes during progression from chronic to acute phase of ATL 44. 
The differences between our and previous study may suggest that such lesions may have 
been occult among our series using conventional CGH based on limitations in its 
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resolution or reflect different pathogenetic events in cases progressing from the chronic 
form compared to the de novo leukemic type of ATLL. Separately, given the number of 
chromosomal anomalies observed, the small number of analyzed cases limited a more 
extensive analysis of association between ATLL genotypes, gene expression profiles, and 
clinical outcomes.  
 
Discussion 
 ATLL is a distinct clinical entity associated with HTLV-1 retroviral infection. 
Regardless of the extensive progress in virology, immunology, and molecular biology of 
ATLL and HTLV-1, the prognosis of patients with ATLL remains poor. Recently, 
several studies suggested that some ATLL patients may respond to the combination of 
AZT-IFNα 14-17; however, factors associated with responsiveness to the treatment are 
presently unknown. Our objective was to identify genetic parameters which might be 
associated with responsiveness to AZT-IFNα combination treatment. In addition, 
application of global gene expression studies to diagnostic specimens might elucidate the 
pathogenesis of ATLL. 
 Our analysis of GEPs of diagnostic leukemic ATLL cells revealed changes 
in gene expression of about 1000 genes, many of which (e.g., IL2Rα, IL2Rβ and major 
histocompatibility complex class II genes) were previously reported to be up-regulated in 
HTLV-1 infected cell lines and tumors27,30,31. Moreover, multiple genes deregulated in 
our cases were also recently reported to be either over-expressed or down-regulated in 
primary ATLL specimens studied by Pise-Masison et al30. Among the prominent genes 
similarly expressed in our cases as well as cases reported by Pise-Masison et al30, we 
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observed high levels of expression of LYN, LYZ, S100A8, S100A9, LMO2, CSPG2 and 
CX3CR1. These observations support the validity of our gene expression measurements 
and analyses, performed on leukemic cells derived from representative ATLL patients 
with characteristic clinical manifestations and clinical course. Anomalous expression of 
the LMO2 protein in ATLL – a transcription factor not normally expressed in normal T 
cells but implicated in the pathogenesis of T-cell acute lymphoblastic leukemias – may 
suggest that it may have a similar role in the pathogenesis of ATLL. The mechanism 
underlying LMO2 expression in ATLL is unknown. We did not detect aberrations at the 
corresponding cytogenetic interval locus 11p13 that might point to genomic 
amplification. It is also highly unlikely that HTLV-1 virus specifically integrates into 
host DNA in the proximity of the LMO2 gene, since previous studies demonstrated 
random integration sites of the virus45,46. Further studies to elucidate the mechanism of 
LMO2 expression and its possible pathogenic role in ATLL are in progress. 
 While our results corroborate some of the findings observed by Pise-Masison et 
al30, some studies analyzing gene expression of HTLV-1 immortalized T cells reported 
different observations with regard to some of the genes. For example, down-regulation of 
the expression of protein tyrosine kinases of the Src and Syk families (e.g. LCK, HCK, 
LYN) has been reported in response to HTLV-129, though we did not observe a similar 
profile among our HTLV-1+ ATLL cases. The latter discrepancy may stem from 
differences in gene expression between primary tumors and HTLV1 infected cell lines. 
Indeed, gene expression analyses presented herein demonstrated marked differences in 
gene expression profiles between MT2 HTLV-1 positive cell line and primary patients’ 
ATLL cells.  
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Expression of genes associated with cell proliferation was among major 
differences distinguishing MT2 from primary ATLL patient samples. Similarly, previous 
studies demonstrated that in vitro HTLV-1 infection induces genes associated with 
proliferation and cell cycling attributed to expression of Tax protein28,29. However, while 
Tax oncogene, encoded by HTLV-1 virus is expressed in many HTLV-1 infected cell 
lines, its expression is lost in many primary ATLL cells and may contribute to the 
observed differences. The differences in gene expression between primary tumors and 
HTLV-1 positive cell lines suggest that although the latter represent an accessible tool for 
study of HTLV-1 infection and lymphomagenesis, aberrations observed in these lines 
may not completely represent changes observed in primary tumor cells. 
 The primary leukemic cells analyzed in this study harbored genetic aberrations 
similar to aberrations previously reported in literature and included frequent 
chromosomal gains of chromosomal regions 3p, 7q, 1q, 2q, 3q, 8p, 8q, 9q, 18q, and 19p 
in addition to losses at chromosomal regions 6q, 2q, 4q, 5q, 10p, 10q, 12p, 18p and 
chromosome 1347,48. Analyses of correlation between chromosomal changes and 
alteration in gene expression of chromosomes located in the chromosomal aberration 
regions demonstrated relatively poor correlation, similar to our observations in 
transformed follicular lymphoma specimens49. 
 Gene expression profiling demonstrated a difference in gene expression between 
ATLL cells responsive and unresponsive to AZT-IFNα combination therapy. Noticeably, 
leukemic cells from non-responsive patients had high expression of E2F3 and many of its 
proliferation-associated oncogenic targets genes, likely reflecting more aggressive nature 
of these tumors. Of interest, ATLL specimens exhibiting response to AZT-IFNα therapy 
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displayed high expression of interferon responsive genes prior to treatment initiation and 
further increase in their expression upon treatment; however, induction of some of these 
genes was also observed in unresponsive cases. The association between treatment and 
induction of interferon inducible genes upon treatment was highly statistically significant. 
Previous studies demonstrated that HTLV-1 may blunt signaling by IFNα50 and the 
extent of this effect may vary between different tumors. Indeed, over-expression of IRF4, 
a regulatory transcription factor negatively regulating IFN responses, has been reported 
as a determinant of resistance in ATLL12. Interferon-gamma expressing mice exhibit 
decreased HTLV1 Tax protein tumorigenesis compared to animals deficient in interferon-
gamma expression, suggesting that endogenously active interferon signaling pathway 
may ameliorate aggressiveness of these tumors3.  However, the precise mechanism 
underlying the baseline differences in interferon target genes among ATLL patients, and 
its association with clinical response to the therapy is presently unknown.  A recent in 
vitro study of ATLL-derived HTLV-1–infected CD4+ T-cell lines treated with arsenic 
trioxide and IFNα also demonstrated up-regulation of similar interferon-induced genes in 
the treated cells undergoing apoptosis and death following treatment11. Similar to our in 
vivo findings that demonstrated changes of gene expression at 24 hours after AZT-IFNα 
combination treatment, induction of interferon target genes upon in vitro treatment with 
arsenic trioxide and IFNα  was already detectable at 12 hours and was sustained up to 48 
hours11.  
The NFκB pathway is known to play an integral role in the pathogenesis of 
HTLV-1 infection and lymphomagenesis12. Suppression of NFκB activation by AZT-
IFNα combination therapy might lead to apoptosis of ATLL cells, as was recently 
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reported for combination of arsenic trioxide and IFNα{Nasr, 2003 #15}, while expression 
of the C-Rel protein, a component of NFκB imparts resistance to AZT-IFNα therapy12. 
However, the exact mechanism of the AZT-IFNα-induced ATLL cell death is presently 
unknown. Demonstration of specific gene expression signatures associated with response 
to therapy may help to further elucidate the exact mechanism of AZT-IFNα-induced 
suppression of NFκB and needs further evaluation in future studies.
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Legends 
Figure 1: Gene Expression in ATLL. Gene expression profiles are depicted for 9 
patients with ATLL, including 6 pre (A) and post AZT-IFNα (B) treatment and two T-
cell lines, MT2 (LLAT 7A and B) and Jurkat (LLAT 8). Each row represents a separate 
cDNA clone on the microarray and each column a separate mRNA sample. The displayed 
matrix represents the relative log-base2 ratio of hybridization of fluorescent cDNA 
probes prepared from each experimental mRNA sample (compared to the median 
expression level across samples), as depicted by the corresponding color scale.  
Figure 2. LMO2 protein expression in primary ATLL leukemic cells Immunoblot 
analysis using the anti-LMO2 monoclonal antibody shows LMO2 protein expression in 
primary ATLL leukemic cells, and the diffuse large B cell cell line SU-DHL6, known to 
express this protein. LMO2 protein is not expressed in the Jurkat and MT2 cells. *- 
empty lane. 
Figure 3: In vivo gene expression responses of patients with ATLL following AZT-
IFNα therapy. A) Gene expression signature of in vivo response to AZT-IFNα was 
defined by selecting those exhibiting significant induction or repression in response to 
AZT-IFNα (n=150)  as determined by SAM, with rows ordered based on the magnitude 
of the difference. The logarithmic difference between the pre- (A) and post- (B) therapy 
measurements for each patient is captured in the depicted heat map.  Selected gene sets 
exhibiting significant enrichment by GSEA (p<0.01, FDR<0.05) in response to AZT-
IFNα are tabulated, with induced and repressed groups represented in B) and C), 
respectively. 
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Figure 4: Chromosomal Aberrations in ATLL Patients. (A) Cumulative gains and 
losses of chromosomal regions in eight Adult T Cell Leukemia patients; (B) 
Representation of the genomic profiling of case LLAT-9 using high-resolution BAC 
array-CGH. Bottom: A number of DNA copy number changes was observed, including 
the gain of 1q, trisomy of chromosome 3, deletion of 6q and deletion of 10p. Inserts: 
details of the genomic gain involving chromosome 1q22-1q32 and the loss of 
chromosome 6q14-q21. The presence of only one chromosome X corresponds to males’ 
samples. 
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Table 1: Gene expression signature of responsiveness to AZT-IFNa treatment. Selected gene sets exhibiting significant 
enrichment by GSEA (p<0.01, FDR<0.2) in distinguishing patients with clinical responses to AZT-IFNα are tabulated. 
Higher in Source Gene Set Annotation 
p-
value 
FDR 
Example 
Enriched Gene(s) 
Primary 
Author 
PMID 
Responders mSIGDB HSA04612_ANTIGEN_PROCESSING_AND_PRESENTATION 
Genes involved 
in antigen 
processing and 
presentation 
<0.001 <0.005 
HLA-
DRB1/B5/B4/DPA, 
HLA-A, B2M, 
TAP2, TAPBP, 
RFX5 
Kanehisa 18077471 
Responders SIGDB IS_161_IFN_PMBC_2X_UP 
Induced >2-fold  
in PBMC by 
IFNA/IFNB in 
vitro (6-hrs) 
<0.001 <0.05 
ISG20, IRF1, 
GBP1, STAT1, 
OAS2, MX1 
Baechler 12604793 
Responders mSIGDB DER_IFNA_UP 
Induced by IFNA 
in fibrosarcoma  
<0.001 <0.05 
IFITM1, IRF1, 
HLA-A, GBP1, 
PSMB8 
Der 9861020 
Responders mSIGDB IFN_GAMMA_UP 
Induced by IFNG 
in fibrosarcoma  
<0.005 <0.05 
IRF1, ICAM1, 
STAT1, IFITM1 
Der 9861020 
Responders mSIGDB IFN_ALPHA_UP 
Induced by IFNA 
in fibrosarcoma  
<0.001 <0.05 
IFITM1, IRF1, 
STAT1, OAS2, 
OAS1 
Der 9861020 
Responders SIGDB IS_162_IFN_PMBC_4X_UP 
Induced >4-fold  
in PBMC by 
IFNA/IFNB in 
vitro (6-hrs) 
<0.001 <0.05 
IRF7, ISG20, 
TNFSF10, LY6E, 
CASP10 
Baechler 12604793 
Non-
responders 
SIGDB IS_171_E2F3_OVEREXPRESSION_2X_UP 
Induced >2-fold 
by E2F3 
<0.001 0.17 
CDKN1C, FZD1, 
PTCH1, HEY1, 
MYB, E2F3 
Bild 16273092 
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Table 2: Differentially Expressed Genes within Chromosomal Aberrations of ATLL 
Lesion/Chromosome               Differentially Expressed Genes                                                                                      
(-) 1p    RPL27A 
(-) 1q UAP1, DAF, FJL10052, FLJ21841, HDGF, ILF2, NUCKS, S100A10, MGC21854, FCER1G 
(-) 2p OLD35, MTHFD2 
(+) 2q IL18R1, GPR55, ITM2C, MGAT4A, TTN, CTLA4, STK17B, PSCDBP 
(+) 3p AXUD1, SNRK, CISH, LRIG1, PCAF 
(-) 3p SATB1 
(+) 3q CCNL1, IFRG28, PLSCR1, TAZ 
(-) 5q CSPG2 
(+) 7p NT5C3 
(+) 7q KIAA1718, TES, UBE2H, LR8, PEG10, FLJ20653 
(-) 7q HIMAP4 
(+) 8p PLEKHA2 
(+) 8q MCM4 
(-) 9q NPDC1, ANXA1, UCK1 
(-) 10p IL2RA, FLJ13267 
(-) 10q IFIT1, ABLIM1, ADD3, MRPS16, SCD, IFIT2 
(-) 11p RPL27A, IRF7, H19 
(+) 11q SWAP70, SERPING1 
(-) 12p NINJ2, LTBR, SLC2A3, LLT1, TNFRSF7 
(-) 12q OSBPL8 
(-) 13q NY-REN-34, ALOX5AP, EBI2, KIAA0853, UBL3 
(-) 15q MYO5A, ISG20, B2M, IL16, GLCE 
(-) 16p NME4, NK4 
(-) 16q MET2A, MET1L, MET1F, COG8, TUBB4, PNAS-108, FLJ20186, SLC7A5 
(-) 17p HS3ST3B1, ITGAE 
(+) 18q MGC10200 
(+) 19p EDG6, MYO1F, JAK3, CTL2, MGC15716 
(+) 19q PIK3AP, LTBP4 
(-) 19q PIK3AP, ZNF134 
(+) Xp KIAA1280 
Genes with at least 1.5-fold difference in relative expression as compared to the average expression across all specimens were considered. In cases with genomic 
gain/amplification (denoted as “+”), only over-expressed genes were considered, while in cases with genomic deletions (denoted as “-“), only genes with 
decreased expression are shown. In bold are genes whose expression changed in two cases.  
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